GlassScriptPhysician profile
Jai Kumar Khatri
NPI 1134483175
$3,684.78
in general payments reported to CMS, 2019-2025
36 companies · $953 in 2025
The $953 reported for 2025 was more than what 95% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2022: $503 · 2023: $410 · 2024: $587 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,786.62 |
| Education | $163.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,336.09 | 2019-2024 | Avvigo Guidance System |
| Shockwave Medical, INC | $378.86 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $198.76 | 2023-2025 | Calquence, Enhertu, Lynparza |
| Medtronic, INC. | $195.53 | 2024-2025 | Cardioblate, Symplicity G3 |
| Edwards Lifesciences Corporation | $184.78 | 2022 | |
| Beigene USA, INC. | $167.05 | 2023-2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $145.17 | 2024-2025 | |
| Astellas Pharma US INC | $112.30 | 2024-2025 | Xospata, Padcev |
| Seagen INC. | $104.12 | 2022-2023 | Tivdak |
| Incyte Corporation | $99.95 | 2024 | |
| Eisai INC. | $82.78 | 2023 | |
| Pfizer INC. | $64.56 | 2024-2025 | |
| Abbott Laboratories | $48.83 | 2023 | Absolute Pro |
| Array Biopharma INC | $42.53 | 2025 | Xalkori, Lorbrena, Braftovi |
| Genzyme Corporation | $35.73 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.94 | 2024-2025 | Welireg, Keytruda |
| Daiichi Sankyo INC. | $33.65 | 2024 | Vanflyta, Enhertu |
| Lilly USA, LLC | $33.55 | 2025 | Verzenio |
| Glaxosmithkline, LLC. | $30.80 | 2025 | Zejula, Ojjaara |
| Genmab U.S., INC. | $30.13 | 2025 | Tivdak |
| Tempus Ai, INC | $28.45 | 2024 | |
| Janssen Biotech, INC. | $28.32 | 2025 | Talvey, Darzalex |
| Azurity Pharmaceuticals, INC. | $25.94 | 2025 | Vivimusta |
| Gilead Sciences, INC. | $24.38 | 2025 | Trodelvy |
| Celgene Corporation | $22.95 | 2025 | Reblozyl |
| Sun Pharmaceutical Industries INC. | $22.78 | 2024 | |
| Tersera Therapeutics LLC | $21.46 | 2025 | Xermelo |
| Pharmacosmos Therapeutics INC. | $20.72 | 2025 | Monoferric |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Genentech USA, INC. | $19.49 | 2024 | Venclexta |
| Deciphera Pharmaceuticals INC. | $18.51 | 2025 | Qinlock |
| Sobi, INC | $15.61 | 2022 | |
| Rigel Pharmaceuticals, INC. | $14.54 | 2024 | Rezlidhia, Tavalisse |
| Recordati_rare_diseases_inc. | $14.27 | 2025 | Enjaymo |
| Abbvie INC. | $13.76 | 2025 | |
| Legend Biotech USA INC. | $13.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jai Kumar Khatri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.